PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 12, 2025PharmaceuticalsOpen Access

Investigating the Therapeutic Mechanisms of Shen-Ling-Bai-Zhu-San in Type 2 Diabetes and Ulcerative Colitis Comorbidity: A Network Pharmacology and Molecular Simulation Approach

View Full Paper
Ask AI
Bookmark
Share

Authors

YQYu QianSSShijie SunTHTao Han

Discussion

Loading...

Member takes

Overview

Network pharmacology reveals SLBZS may improve immune responses and insulin sensitivity in T2D-UC comorbidity.

Key Points

  • SLBZS shows potential for treating type 2 diabetes and ulcerative colitis through immune and metabolic modulation.
  • Key findings indicate that flavonoids in SLBZS target the SLC6A14/PI3K–AKT signaling axis, enhancing insulin sensitivity.
  • The study utilized multi-omics strategies, including network pharmacology and molecular docking simulations, to uncover interactions.
  • Results suggest that SLBZS may address both inflammatory and metabolic processes, providing insights for clinical applications.

Cite This Study

Qian et al. (2025) studied this question.

synapsesocial.com/papers/68eb8fe250220ac955d94bf9https://doi.org/10.3390/ph18101516
View Full Paper
Ask AI
Bookmark
Share